Details

Autor(en) / Beteiligte

• Schweizer, Juliane
• Arnold, Markus
• König, Inke R
• Bicvic, Antonela
• Westphal, Laura P
• Schütz, Valerie
• Inauen, Corinne
• Scherrer, Natalie
• Luft, Andreas
• Galovic, Marian
• Ferreira Atuesta, Carolina
• Pokorny, Thomas
• Arnold, Marcel
• Fischer, Urs
• Bonati, Leo H
• De Marchis, Gian Marco
• Kahles, Timo
• Nedeltchev, Krassen
• Cereda, Carlo W
• Kägi, Georg
• Bustamante, Alejandro
• Montaner, Joan
• Ntaios, Georg
• Sagris, Dimitrios
• Foerch, Christian
• Spanaus, Katharina
• von Eckardstein, Arnold
• Katan, Mira

Titel

Measurement of Midregional Pro-Atrial Natriuretic Peptide to Discover Atrial Fibrillation in Patients With Ischemic Stroke

Ist Teil von

• Journal of the American College of Cardiology, 2022-04, Vol.79 (14), p.1369-1381

Ort / Verlag

United States

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Midregional pro-atrial natriuretic peptide (MR-proANP) is a promising biomarker to differentiate the underlying etiology of acute ischemic stroke (AIS). This study aimed to determine the role of MR-proANP for classification as cardioembolic (CE) stroke, identification of newly diagnosed atrial fibrillation (NDAF), and risk assessment for major adverse cardiovascular events (MACE). This study measured MR-proANP prospectively collected within 24 hours after symptom-onset in patients with AIS from the multicenter BIOSIGNAL (Biomarker Signature of Stroke Aetiology) cohort study. Primary outcomes were CE stroke etiology and NDAF after prolonged cardiac monitoring, as well as a composite outcome of MACE (recurrent cerebrovascular events, myocardial infarction, or cardiovascular death) within 1 year. Logistic/Poisson and subproportional hazard regression were applied to evaluate the association between MR-proANP levels and outcomes. Additionally, a model for prediction of NDAF was derived and validated as a decision tool for immediate clinical application. Between October 1, 2014, and October 31, 2017, this study recruited 1,759 patients. Log MR-proANP levels were associated with CE stroke (OR: 7.96; 95% CI: 4.82-13.14; risk ratio: 3.12; 95% CI: 2.23-4.37), as well as NDAF (OR: 35.3; 95% CI: 17.58-71.03; risk ratio: 11.47; 95% CI: 6.74-19.53), and MACE (subdistributional HR: 2.02; 95% CI: 1.32-3.08) during follow-up. The model to predict NDAF including only age and MR-proANP levels had a good discriminatory capacity with an area under the curve of 0.81 (95% CI: 0.76-0.86), was well calibrated (calibration in the large: -0.086; calibration slope 1.053), and yielded higher net-benefit compared with validated scores to predict NDAF (AS5F score, CHA DS -VASc [Congestive Heart Failure, Hypertension, Age ≥65 or ≥75, Diabetes, Prior Cardioembolic Event, (female) Sex, or Vascular Disease] score). MR-proANP is a valid biomarker to determine risk of NDAF and MACE in patients with AIS and can be used as a decision tool to identify patients for prolonged cardiac monitoring. (Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL study [BIOSIGNAL]; NCT02274727).